お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ

株式会社グローバルインフォメーション
表紙
市場調査レポート
商品コード
979399

非小細胞肺がん (NSCLC):疫学予測 (~2029年)

Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029

出版日: | 発行: GlobalData | ページ情報: 英文 58 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=104.84円
非小細胞肺がん (NSCLC):疫学予測 (~2029年)
出版日: 2020年12月31日
発行: GlobalData
ページ情報: 英文 58 Pages
納期: 即納可能 即納可能とは
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の主要8カ国における非小細胞肺がん (NSCLC) の18歳以上の診断症例数は、2019年に79万4999例を示しました。地域別で見ると、中国都市部が301,036例で最大のシェアを占め、スペインが29,977例で最小のシェアを示しました。また、予測期間中は3.01%のCAGRで推移し、2029年の診断症例数は103万4554例に増加すると予測されています。

当レポートでは、世界の主要8カ国における非小細胞肺がん (NSCLC) の市場を調査し、疾患の概要、病因・病態生理、発症数の推移・予測、各種区分別の内訳、将来の展望などをまとめています。

第1章 目次

第2章 エグゼクティブサマリー

第3章 疫学

  • 疾患の背景
  • 危険因子・併存疾患
  • 世界的動向・歴史的動向
  • 予測調査手法
  • 疫学予測
    • 診断症例数
    • 診断症例数:男女別
    • 診断症例数:年齢別
    • 診断症例数:ステージ別
    • 診断症例数:組織型別
    • 診断症例数:ゲノムバイオマーカー・EGFR・KRAS変異別
    • 診断症例数:変異別
    • 5カ年診断済み患者数
  • ディスカッション

第4章 付録

図表

List of Tables

List of Tables

  • Table 1: Summary of Newly Added Data Types and Countries
  • Table 2: Summary of Updated Data Types
  • Table 3: Risk Factors and Comorbidities for NSCLC
  • Table 4: 8MM, Diagnosed Incident Cases of NSCLC by Stage at Diagnosis, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 5: 8MM, Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Immunotherapy and Genomic Biomarkers, Ages ≥18 Years, Both Sexes, N, 2019
  • Table 6: 8MM, Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations, Ages ≥18 Years, Both Sexes, N, 2019

List of Figures

List of Figures

  • Figure 1: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019 and 2029
  • Figure 2: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages ≥18 Years, N, 2019 and 2029
  • Figure 3: 8MM, Diagnosed Incidence of
目次
Product Code: GDHCER262-20

Non-Small Cell Lung Cancer - Epidemiology Forecast to 2029

Lung cancer is a disease of uncontrolled cell growth in the lung tissues. It is one of the most commonly occurring cancers in the world (International Agency for Research on Cancer, 2018). There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Other less common types of lung tumors include lung carcinoid tumors, adenoid cystic carcinomas, lymphomas, and sarcomas. Benign lung tumors such as hamartomas are rare. NSCLC is the most common type of lung cancer, making up about 85% of all lung cancers. SCLC accounts for 10-15% of lung cancers, while carcinoid tumors are the rarest, occurring in fewer than five percent of lung cancers (American Cancer Society, 2016). The majority of lung cancer cases are attributable to smoking. However, a sizable portion of cases occur in non-smokers, implying that genetic components, family history, and environmental exposure also play a prominent role in the development of the disease (American Cancer Society, 2016).

In 2019, there were 794,999 diagnosed incident cases of NSCLC in men and women combined, ages 18 years and older, in the 8MM. Urban China accounted for the largest share of these cases with 301,036 diagnosed incident cases, while Spain accounted for the smallest share with 29,977 cases in 2019. GlobalData epidemiologists forecast an increase in the diagnosed incident cases of NSCLC to 1,034,554 cases in 2029 in the 8MM at an Annual Growth Rate (AGR) of 3.01% during the forecast period. In 2019, there were 1,060,302 five-year diagnosed prevalent cases of NSCLC in men and women combined, ages 18 years and older, in the 8MM. Urban China accounted for the largest share of these cases with 354,667 cases, while Spain accounted for the smallest share with 25,831 cases in 2019. The five-year diagnosed prevalent cases of NSCLC will increase to 1,370,422 cases in 2029 at an AGR of 2.92% during the forecast period.

Scope

  • The Non-Small Cell Lung Cancer (NSCLC) Epidemiology Report provides an overview of the risk factors and the global and historical trends for NSCLC in the eight major markets (8MM: US, France, Germany, Italy, Spain, UK, Japan, and urban China). The report includes diagnosed incident cases and five-year diagnosed prevalent cases of NSCLC in these markets from 2019-2029.
  • The incident cases are further segmented by sex and age (18-39 years, 40-59 years, 60-79 years, and 80 years and older), by cancer stage at diagnosis (stages IA, IB, IIA, IIB, IIIA, IIIB, IIIC, and IV), and by cancer histology subtype (non-squamous cell carcinoma [adenocarcinoma, large cell carcinoma, and others] and squamous cell carcinoma). Diagnosed incident cases of non-squamous cell carcinoma are further segmented by mutations, specifically immunotherapy biomarkers, and genomic biomarkers. Diagnosed incident cases of non-squamous cell carcinoma EGFR are segmented by subtypes. Diagnosed incident cases of non-squamous cell carcinoma KRAS were segmented by subtypes. The diagnosed incident cases of squamous cell carcinoma are segmented by mutations.
  • The NSCLC epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The Epidemiology Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

Reasons to Buy

The NSCLC Epidemiology series will allow you to -

  • Develop business strategies by understanding the trends shaping and driving the global NSCLC market.
  • Quantify patient populations in the global NSCLC market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups that present the best opportunities for NSCLC therapeutics in each of the markets covered.
  • Understand magnitude of NSCLC by stage at diagnosis, histology types, and biomarkers.

Table of Contents

1 Table of Contents

  • 1.1 List of Tables
  • 1.2 List of Figures

2 Non-Small Cell Lung Cancer: Executive Summary

  • 2.1 Catalyst
  • 2.2 Related Reports
  • 2.3 Upcoming Reports

3 Epidemiology

  • 3.1 Disease Background
  • 3.2 Risk Factors and Comorbidities
  • 3.3 Global and Historical Trends
  • 3.4 Forecast Methodology
    • 3.4.1 Sources
    • 3.4.2 Forecast Assumptions and Methods
    • 3.4.3 Diagnosed Incident Cases of NSCLC
    • 3.4.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 3.4.5 Diagnosed Incident Cases of NSCLC by Histological Types
    • 3.4.6 Mutations Among Diagnosed Incident Cases of Non-Squamous Cell Carcinoma and Squamous Cell Carcinoma
    • 3.4.7 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 3.5 Epidemiological Forecast for NSCLC, 2019-2029
    • 3.5.1 Diagnosed Incident Cases of NSCLC
    • 3.5.2 Sex-Specific Diagnosed Incident Cases of NSCLC
    • 3.5.3 Age-Specific Diagnosed Incident Cases of NSCLC
    • 3.5.4 Diagnosed Incident Cases of NSCLC by Stage at Diagnosis
    • 3.5.5 Diagnosed Incident Cases of NSCLC by Histological Type
    • 3.5.6 Diagnosed Incident Cases of Non-Squamous Cell Carcinoma by Mutations: Genomic Biomarkers, EGFR and KRAS Mutations
    • 3.5.7 Diagnosed Incident Cases of Squamous Cell Carcinoma by Mutations
    • 3.5.8 Five-Year Diagnosed Prevalent Cases of NSCLC
  • 3.6 Discussion
    • 3.6.1 Epidemiological Forecast Insight
    • 3.6.2 COVID-19 Impact
    • 3.6.3 Limitations of the Analysis
    • 3.6.4 Strengths of the Analysis

4 Appendix

  • 4.1 Bibliography
  • 4.2 About the Authors
    • 4.2.1 Epidemiologist
    • 4.2.2 Reviewers
    • 4.2.3 Global Director of Therapy Analysis and Epidemiology
    • 4.2.4 Global Head and EVP of Healthcare Operations and Strategy
  • 4.3 About GlobalData
  • 4.4 Contact Us
  • 4.5 Disclaimer
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.